The objective of the study is to establish the predictive value of early blood gene
expression signature of Benralizumab response associated with a significant reduction of the
number of exacerbations in treated severe asthmatic patients.
This trial is a French, multicenter and no-randomized trial. Patients enrolled will be
clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6
clinical visit on site and in phone call at 13 months)